ReviewInternational journal of nanomedicine2026
Recent Advances in Mitochondria-Targeted Nano-Drug Delivery Systems for Cancer Therapy.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- L-Arginine-Modified Chitosan Curcumin Nanocrystals Target M1 Macrophages via CAT-2/Clathrin-Mediated Endocytosis for Mitochondrial Protection and ALI/ARDS Therapy.Pharmaceutics · 2026Article
- Nanoscale biointerfaces in inter-organelle communication: membrane contact sites, organelle trafficking, and cell fate control.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major disease that poses a serious threat to human health. Conventional treatments such as radiotherapy, chemotherapy, and surgery are limited by systemic toxicity and tumor recurrence, which hinder the achievement of highly efficient and specific therapy. The development of nanodrug delivery systems has provided new opportunities for cancer treatment. Utilizing mechanisms such as passive targeting (eg, the EPR effect) and active targeting (eg, peptide-based surface modification), these systems can precisely deliver drugs to tumor sites, thereby significantly reducing systemic toxicity. In recent years, research focus has shifted from tissue-level targeting to subcellular organelle targeting, particularly of mitochondria. Functioning as cellular power plants, mitochondria are deeply involved in tumor initiation, progression, and the regulation of apoptosis, making them important targets for cancer therapy. Based on the structural features of mitochondria and their dysfunctional role in cancer, this review systematically explores strategies for mitochondria-targeted nanodrug delivery and summarizes the latest research advances along with future directions in cancer treatment. A unique aspect of this review is its systematic integration of the design principles from mitochondrial substructure characteristics to multi-level targeting strategies, underscoring the innovative potential of nanocarriers in overcoming tumor drug resistance and enabling precise intervention. This work thereby provides a theoretical basis and novel insights for precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.